Pharmacogenomics and Post-Operative Nausea and Vomiting

Overview

About this study

The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • A Mayo Clinic patient scheduled to undergo any bariatric surgical procedure, including Roux-en-Y gastric bypass, sleeve gastrectomy, or duodenal switch.
  • Patient age 18 or above.
  • Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures.
  • Patient is willing to engage in a medication adjustment as part of their clinical visit (when needed).

Exclusion Criteria

  • Patient with uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
  • Any patient who will be unable to have genetic testing at minimum of 1 week  prior to scheduled surgery or with allergies to ondansetron or granisetron.
  • Any patient with prior pharmacogenomics testing that is readily available in the medical record will be excluded from this study.
  • Any patient that is pregnant.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yvette Martin McGrew, M.D., Ph.D.

Closed for enrollment

Contact information:

Anita Stoltenberg R.R.T., L.R.T.

(507)422-0582

Stoltenberg.Anita@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20403523

Mayo Clinic Footer